Skip to NavigationSkip to content

Merck KGaA

Bavencio Phase 3 head and neck cancer trial terminated

Merck KGaA, its biopharma division EMD Serono, and Pfizer have announced their decision to terminate their ongoing Phase 3 trial of the checkpoint inhibitor Bavencio (avelumab) after it became apparent following an independent Data Monitoring Committee interim analysis that the drug was unlikely to achieve its primary endpoint.

The drug was being tested in combination with chemoradiotherapy (CRT) for the treatment of untreated locally advanced squamous cell carcinoma of the head and neck.

Merck KGaA to flog Allergopharma business to Dermapharm

German-based drugmaker Merck KGaA has confirmed its intention to divest its allergy business Allergopharma to Dermapharm, another German manufacturer of generics, dietary products, cosmetics and medical devices.

The business unit generated €88 million for Merck in 2018. It is currently developing a competitor to Mylan’s flagship EpiPen epinephrine autoinjector as a treatment for anaphylactic reactions.

The agreement includes Allergopharma’s therapeutic and diagnostic portfolio, but also its production site located in Reinbek, Germany.

Realising the potential of greater collaboration for women living with cancer

Published on 27/01/20 at 11:44am

Following the launch of a new global report, 'Supporting women with cancer', Lynn Talyroe, Senior Vice President, Head of Healthcare Global Government and Public Affairs, Head of Corporate & Government Relations USA at Merck KGaA, discusses the unique challenges faced by women living with cancer and the importance of providing more tailored support.

Despite the number of policies aimed at eliminating and reducing risk factors, and promoting early detection, the number of cancer cases continues to rise globally.

Bavencio extends survival at Phase 3 in previously untreated locally advanced or metastatic urothelial carcinoma

Bavencio (avelumab), the anti-programmed death ligand-1 (PD-L1) antibody co-developed by Pfizer and Merck KGaA’s biopharma unit EMD Serono, has been shown to extend survival in patients with previously untreated locally advanced or metastatic urothelial carcinoma (UC).

The Phase 3 data revealed that the therapy, in combination with best supportive care (BSC), demonstrated a “statistically significant improvement” in overall survival compared to BSC alone, meeting the study’s primary endpoint.

New report reveals shocking knowledge gaps around type 2 diabetes risk factors

A new report released on World Diabetes Day has shone a light on a startling lack of knowledge surrounding type 2 diabetes, a condition that accounts for around 90% of the over 450 million cases of diabetes worldwide, according to the World Health Organization.

The report, released by Merck KGaA and conducted by YouGov, collated the responses of 9,350 adult participants across nine countries: Brazil, Mexico, Russia, United Arab Emirates, Malaysia, Vietnam, China, Saudi Arabia and Chile.

Pfizer and Merck KGaA's Bavencio falls short of primary endpoint in Phase 3 gastric cancer trial

Pfizer and Merck KGaA’s EMD Serono have lifted the lid on new Phase 3 data for Bavencio (avelumab) in the treatment of gastric cancer, and they were not the promising kind.

In evaluating the therapy for maintenance treatment following induction chemotherapy in unresectable, locally advanced or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) cancer, the companies found that while it showed clinical activity, it failed to outclass chemotherapy or best supportive care with regards to extend overall survival.

Bavencio+Inlyta combo OK'd in Europe for first-line advanced kidney cancer

Merck KGaA and Pfizer’s joint drug Bavencio (avelumab) has received European approval in combination with Inlyta (axitinib) in the first-line treatment of adult patients with advanced renal cell carcinoma (RCC), it has emerged.

The decision follows that of the FDA in the same indication, made earlier this year in May, and is based on findings that demonstrate that the combo “significantly lowered risk of disease progression or death” by 31% compared to Pfizer’s Sutent in advanced RCC patients regardless of PD-L1 status.

Insider Interview: A roadblock for counterfeit drugs?

Published on 08/07/19 at 12:32pm

Dr Thomas Endress, Founder, and Dr Frederic Berkermann, co-?Founder, of a new technology being developed at the Merck Innovation Center explain the benefits of a novel solution whixch leverages blockchain to reinforce drug counterfeiting precautions and countermeasures.

Can you provide a bit of background on blockchain and explain the basics of how it works?

Pfizer & Merck's Inlyta combo becomes first FDA-approved anti-PD-L1 therapy for kidney cancer

The FDA has approved Bavencio (avelumab) in combination with Inlyta (axitinib) for the treatment of advanced renal cell carcinoma (RCC). The decision was announced by the drug’s co-developers Merck KGaA and Pfizer, and marks the first FDA approval for an anti-PD-L1 therapy as part of a combination regimen in this indication.

Around 20-30% of new diagnoses in RCC are made at an advanced stage, and almost a tired of early-stage diagnoses go on to develop metastases, meaning there is a considerable unmet need for first-line treatment which safely delay progression of the disease.

Pfizer and Merck discontinue Phase 3 avelumab ovarian cancer trial

Pfizer and Merck KGaA have chosen to discontinue the Phase 3 JAVELIN trial looking into avelumab in combination with chemotherapy as a treatment for advanced ovarian cancer.

The discontinued trial sought to investigate avelumab in combination with chemotherapy followed by maintenance therapy of avelumab in combination with talazoparib versus an active comparator in treatment-naïve patients with locally advanced or metastatic ovarian cancer (Stage III or Stage IV).

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches